Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Aortopathy
US10933119B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10933119-B2 |
| Application number | US-201615553204-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 19, 2016 |
| Priority date | Feb 25, 2015 |
| Publication date | Mar 2, 2021 |
| Grant date | Mar 2, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to aortopathy, and in particular, to compositions and methods for the diagnosis and treatment of aortopathy.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating or ameliorating aortic intramural hematoma progression or recurrence in a subject in need of such treatment, the method comprising administering, to the subject, a therapeutically effective amount of a granulocyte macrophage colony-stimulating factor (GM-CSF) negative modulator. 2. A method according to claim 1 , wherein the negative modulator comprises an anti-GM-CSF antibody or antigen-binding fragment thereof. 3. A method according to claim 2 , wherein the anti-GM-CSF antibody or antigen-binding fragment thereof specifically binds to SEQ ID No:2, or a variant or fragment thereof. 4. A method according to claim 3 , wherein the antibody is the antibody derived from hybridoma clone MP1-22E9 or the antibody designated as sc-377039, clone number A-6. 5. A method according to claim 2 , wherein the antibody or antigen-binding fragment thereof comprises a monoclonal antibody or an antigen-binding fragment thereof, or wherein the antibody is a human or humanised antibody. 6. A method according to claim 2 , wherein the antibody is the antibody designated as sc-377039, and is derived from hybridoma clone number A-6.
Assignees
Inventors
Classifications
- A61K39/39541Primary
against normal tissues, cells · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
alpha-Glycoproteins · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10933119B2 cover?
- The invention relates to aortopathy, and in particular, to compositions and methods for the diagnosis and treatment of aortopathy.
- Who is the assignee on this patent?
- Univ Leicester
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39541. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).